The clinical outcomes of the GEMINI 1 and GEMINI 2 studies are discussed in this touchOPHTHALMOLOGY interview with Prof. Christopher Lievens (Southern College of Optometry, Memphis, Tennessee, USA). If approved, AGN-190584 is expected to be the first eye drop for the treatment of presbyopia, the eye’s reduced ability to focus on near objects.
The presentation entitled ‘Extended Depth of Focus from AGN-190584 in GEMINI 1 and GEMINI 2 Pooled Phase 3 Studies’ was presented at the The Association for Research in Vision and Ophthalmology, May 01-04, 2022
Questions:
- What is AGN-190584 and what is the rationale for its use in the treatment of presbyopia?
- What have the GEMINI studies taught us about the efficacy and safety of AGN-190584 in this indication?
- What were the aims and design of the current analysis?
- What were the study findings and what have they taught us about the action of AGN-190584?
- What questions remain unanswered and what future studies are planned?
Disclosures: Christopher Lievens is a consultant for and received grant/research support from Allergan.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the virtual ARVO 2022.
